Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

Summary

This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer or advanced kidney cancer.

Timeline

Start

2026-06-01

Primary completion

2028-06-01

Completion

2028-09-01

Drugs

Indications